Arcede Pharma is a pharmaceutical company. The company conducts research and development in the area of chronic obstructive pulmonary disease, including abbreviated COPD, and severe asthma. The company's product portfolio includes a number of drugs intended for the treatment and alleviation of the above ailments. The largest operations are in the Nordic market. The company was established via a spin-off of Respiratorius in 2022 and is headquartered in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Christer Fåhraeus | 11,24 | 11,24 | 2022-12-28 |
| Avanza Pension | 6,89 | 6,89 | 2022-12-28 |
| Valcuria Holding AB | 3,86 | 3,86 | 2022-12-28 |
| Ben Hayes | 2,34 | 2,34 | 2022-12-28 |
| Hans Harvig | 1,72 | 1,72 | 2022-12-28 |
| Shabo Investment Group AB | 1,70 | 1,70 | 2022-12-28 |
| Nordnet Pensionsförsäkring | 1,30 | 1,30 | 2022-12-28 |
| Benny Bengtsson | 1,18 | 1,18 | 2022-12-28 |
| Andreas Bylin | 1,11 | 1,11 | 2022-12-28 |
| Ted Nilsson | 1,07 | 1,07 | 2022-12-28 |
2023-02-13 Bokslutskommuniké 2023
2023-05-12 Årsstämma 2023